Logo.png
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06. Dezember 2024 08:35 ET | GRI Bio, Inc.
Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
Logo.png
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
15. Oktober 2024 08:00 ET | Palisade Bio, Inc.
Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
GEN1ELogo.png
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
14. Oktober 2024 06:02 ET | GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
Logo.png
GRI Bio Regains Compliance with Nasdaq
08. Juli 2024 09:05 ET | GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Logo.png
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
29. April 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces 1-for-15 Reverse Stock Split
03. April 2024 17:30 ET | Palisade Bio, Inc.
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and...
Dyadic Logo Current.jpg
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
26. März 2024 08:30 ET | Dyadic International, Inc.
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...
Emergen logo.png
Biopharmaceutical Market Size Worth USD 1651.4 Billion in 2032 | Emergen Research
15. Januar 2024 11:00 ET | Emergen Research
Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global biopharmaceutical market size was USD 411.4 Billion in 2022 and is expected to register a rapid revenue CAGR of 15.2% during the forecast...
Logo.png
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
27. November 2023 08:35 ET | GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
cmi_logo.png
[Latest] Global Acne Treatment Market Size/Share Worth USD 18.77 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
22. November 2023 23:30 ET | Custom Market Insights
Austin, TX, USA, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acne Treatment Market Size, Trends and Insights By Product Type (Topical...